Hamburg, Germany, November 19, 2026
Evotec SE and Bristol Myers Squibb (BMS) have announced a significant milestone in their strategic protein degradation partnership, receiving a second Investigational New Drug (IND) acceptance from the U.S. Food and Drug Administration (FDA) for a novel molecular glue degrader drug candidate. The newly accepted investigational candidate is a cereblon E3 ligase modulator (CELMoD) and is expected to enter a Phase 1 clinical trial in 2027. This achievement strengthens the companies’ collaborative drug discovery and development pipeline, highlighting the potential of advanced protein degradation technologies to address diseases involving proteins that are difficult to target using conventional medicines. The announcement also demonstrates continued progress in the companies’ long-standing collaboration, which combines Evotec’s advanced multi-omics screening, artificial intelligence (AI)-supported data analytics and drug design capabilities with Bristol Myers Squibb’s specialized CELMoD compound library. The partnership aims to develop innovative molecular glue degraders for high-value biological targets across oncology and other therapeutic areas.
Second IND Acceptance Advances Molecular Glue Pipeline
The second FDA IND acceptance represents an important regulatory milestone for the Evotec and Bristol Myers Squibb collaboration. The newly accepted candidate is designed using molecular glue degrader technology, an emerging therapeutic approach that promotes the selective degradation of disease-associated proteins rather than simply blocking their activity. The candidate belongs to the CELMoD (cereblon E3 ligase modulator) class, which works by inducing interactions between cereblon (CRBN), a component of an E3 ubiquitin ligase complex, and specific target proteins. This interaction triggers a biological process known as ubiquitination, which marks the recruited proteins for degradation by the cell’s natural protein disposal machinery. By redirecting this cellular mechanism toward disease-related proteins, molecular glue degraders may provide opportunities to target biological pathways that have remained challenging for conventional small-molecule drug development. Importantly, the second candidate has not yet entered human clinical testing. Evotec expects it to advance into a Phase 1 clinical trial in 2027, where its safety, tolerability and appropriate dosing will be evaluated. The companies have not publicly disclosed the candidate’s identity or specific therapeutic indication.
AI and Multi-Omics Technologies Drive Drug Discovery
The strategic partnership between Evotec and Bristol Myers Squibb was originally established in 2018 and subsequently expanded in 2022 to accelerate the discovery and development of molecular glue degraders. The collaboration brings together complementary scientific capabilities from both organizations. Evotec contributes its proprietary PanOmics and PanHunter platforms, which integrate large-scale biological data generated through proteomics and transcriptomics technologies. These platforms enable researchers to examine complex cellular mechanisms, identify promising therapeutic targets and evaluate potential drug candidates through comprehensive biological profiling. Additionally, Evotec applies AI and machine learning-based data analytics to support target identification, candidate selection and drug design. Bristol Myers Squibb contributes its specialized library of CELMoD agents and expertise in molecular glue drug discovery. By combining these capabilities, the partnership aims to identify novel molecular interactions and develop compounds capable of selectively eliminating disease-associated proteins. The collaboration is focused on expanding the therapeutic potential of protein degradation across oncology and other areas where significant unmet medical needs remain. According to Evotec, the progression of a second candidate to IND acceptance demonstrates the productivity and repeatability of its discovery platform.
First Partnership Candidate Already in Phase 1 Development
The latest regulatory achievement follows the advancement of the first drug candidate developed under the Evotec and Bristol Myers Squibb partnership, which entered a Phase 1 clinical trial in March 2026 for patients with advanced clear cell renal cell carcinoma, a type of kidney cancer. The progression of two separate candidates to the IND stage highlights the growing productivity of the collaboration and its potential to generate a broader pipeline of investigational medicines. Molecular glue degraders are particularly promising because conventional drug discovery approaches have struggled to develop effective medicines against many proteins that lack suitable binding sites. Through targeted protein degradation, researchers aim to expand the range of proteins that can be therapeutically addressed. This approach could open new opportunities for developing treatments against previously difficult-to-drug targets. However, the clinical potential of each investigational candidate will need to be established through carefully designed human studies. The second candidate’s anticipated Phase 1 entry in 2027 will represent the next important development milestone.
Overall, the second FDA IND acceptance marks a significant advancement in protein degradation research and biotechnology drug development. The collaboration between Evotec and Bristol Myers Squibb demonstrates how combining AI-driven discovery, multi-omics technologies and specialized molecular glue expertise can support the development of innovative therapeutic candidates. As both companies continue advancing their partnered pipeline, future clinical studies will provide important insights into the safety and therapeutic potential of next-generation CELMoD medicines.
Source: Evotec, Bristol Myers Squibb press release



